RDUS Radius Health, Inc.

+0  (1%)
Previous Close 37.73
Open 38.06
Price To book 5.30
Market Cap 1.65B
Shares 43,186,000
Volume 701,939
Short Ratio 7.78
Av. Daily Volume 700,400

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b data due 1H 2017.
Vasomotor symptoms
PDUFA date originally scheduled for March 30 2017 delayed by three months to June 30, 2017.

Latest News

  1. This Is Why Radius Health Inc. Tumbled 8.6% in March
  2. Radius Health Announces Presentations at Upcoming Conferences and Its Plans to Announce First Quarter Financial Results on May 3, 2017
  3. New Analysis from ACTIVE Showed Consistent Fracture Reductions for Abaloparatide-SC Across Geographies
  4. Radius Health Announces Three Presentations on Elacestrant (RAD1901) and RAD140 at the 2017 American Association for Cancer Research Annual Meeting (AACR)
  5. Radius Health (RDUS) Down 11.6% Since Earnings Report: Can It Rebound?
  6. 5 Stocks Insiders Love Right Now
  7. Is The Radius Health Inc (RDUS) Dip A Discount Opportunity?
  8. Falling Biotechs: Cara Reports Zero Sales, Ionis Downgraded
  9. Waltham-based Radius Health faces 3-month delay on drug approval
  10. Radius Health Receives Notification of PDUFA Extension for Abaloparatide-SC
  11. 5 FDA Decisions to Watch Out for in Mar 2017
  12. 5 Small-Cap Biotech Stocks to Buy in March
  13. Radius Health to Present at Cowen and Company 37th Annual Health Care Conference
  14. Radius Health (RDUS) Posts Wider Loss in Q4
  15. Edited Transcript of RDUS earnings conference call or presentation 23-Feb-17 9:30pm GMT
  16. Radius Health Reports Fourth Quarter and Full Year 2016 Financial and Operating Results
  17. Mayo Clinic Proceedings Publishes Positive Results from the ACTIVExtend Clinical Trial of Abaloparatide-SC in Postmenopausal Women With Osteoporosis